About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
Not Voodoo

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
Realizations in Biostatistics
ChemSpider Blog
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Eye on FDA
Chemical Forums
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa

Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
Gene Expression (I)
Gene Expression (II)
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net

Medical Blogs
DB's Medical Rants
Science-Based Medicine
Respectful Insolence
Diabetes Mine

Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem

Politics / Current Events
Virginia Postrel
Belmont Club
Mickey Kaus

Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Why Pfizer? | Main | Things I Won't Work With: Azidotetrazolate Salts »

January 7, 2009

New Chemistry

Email This Entry

Posted by Derek

So I see that Nature Chemistry looks to be fueling up to launch. I’m curious to see how that one will do. The other Nature journals have done pretty well at preserving the prestige of the name, but I hope that they haven’t reached the point of diminishing returns just when they get to my specialty.

And this will be unusual, since you don’t see many attempts to launch a high-end journal from scratch. Most new journals aim for the middle (or worse), figuring that that’s where the papers will come from. But Nature Chemistry will presumably try to compete with JACS and Angewandte Chemie. My guess is that they’ll be able to do that, which means that the journals one tier down will be the ones that feel the consequences. On the other hand, it’s not like Nature has a reputation for paying much attention to chemistry over the years, so perhaps the cachet won’t carry over in the same way that it did for, say, Nature Medicine. We shall see. . .

Comments (2) + TrackBacks (0) | Category: The Scientific Literature


1. anon on January 7, 2009 2:36 PM writes...

JACS, high end? Not in recent decades. Lots of nanocrap.

And I think the ACS spends all their publication budget on making the on-line access pages ever more confusing.

I'll check out Nature Chemistry. Could be good.

Permalink to Comment

2. eugene on January 7, 2009 7:47 PM writes...

Really, competing with JACS and Andjewandte? What about Chem. Comm.? I'm writing up something for, I think Chem. Comm., but I noticed this Nature Chemistry journal, and was thinking about submitting there. Looks like they'll scoff at me if what you say is true. Although, I suppose this paper could be accepted at JACS on an off day.

I'm guessing I shouldn't try for the first few issues of Nature Chemistry anyways.

Permalink to Comment


Remember Me?


Email this entry to:

Your email address:

Message (optional):

The Last Post
The GSK Layoffs Continue, By Proxy
The Move is Nigh
Another Alzheimer's IPO
Cutbacks at C&E News
Sanofi Pays to Get Back Into Oncology
An Irresponsible Statement About Curing Cancer
Oliver Sacks on Turning Back to Chemistry